David D. O'Toole net worth and biography

David O'Toole Biography and Net Worth

David O’Toole has more than 30 years of experience in the accounting and finance sectors, with emphasis on mergers & acquisitions, fund raising, SEC reporting and operational excellence. For the past 17 years his industry focus has been on medical devices, diagnostics and therapeutics. Prior to Opiant, he was Senior Vice President and Chief Financial Officer at Soleno Therapeutics, Inc., a company that he took public in November of 2014 and raised in excess of $40 million from numerous financing transactions. He was also Senior Vice President and Chief Financial Officer at Codexis, Inc. (2012-2014), a public company focused on developing biocatalysts, Response Genetics, Inc., (2011-2012), a public company focused on cancer diagnostics and was Executive Vice President and Chief Financial Officer of Abraxis Bioscience, Inc. (2008-2010), a public company focused on cancer therapeutics.

David began his career in public accounting with 8 years at Arthur Andersen and then 16 years at Deloitte & Touche LLP, where he served for 12 of those years as a partner. He has a Bachelor of Science degree in accounting from the University of Arizona, and is a certified public accountant.

What is David D. O'Toole's net worth?: The estimated net worth of David D. O'Toole is at least $0.00 as of December 5th, 2024. Mr. O'Toole owns 23,734 shares of Opiant Pharmaceuticals stock worth more than $0 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. O'Toole may own. Learn More about David D. O'Toole's net worth.
How do I contact David D. O'Toole?: The corporate mailing address for Mr. O'Toole and other Opiant Pharmaceuticals executives is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. Opiant Pharmaceuticals can also be reached via phone at (310) 598-5410 and via email at [email protected]. Learn More on David D. O'Toole's contact information.
Has David D. O'Toole been buying or selling shares of Opiant Pharmaceuticals?: David D. O'Toole has not been actively trading shares of Opiant Pharmaceuticals during the last ninety days. Most recently, David D. O'toole sold 541 shares of the business's stock in a transaction on Friday, January 27th. The shares were sold at an average price of $20.26, for a transaction totalling $10,960.66. Following the completion of the sale, the chief financial officer now directly owns 34,248 shares of the company's stock, valued at $693,864.48. Learn More on David D. O'Toole's trading history.
Who are Opiant Pharmaceuticals' active insiders?: Opiant Pharmaceuticals' insider roster includes Craig Collard (Director), Roger Crystal (CEO), David O'Toole (CFO), Matthew Ruth (Insider), Michael Sinclair (Director), Phil Skolnick (Insider), and Thomas Thomas (Director). Learn More on Opiant Pharmaceuticals' active insiders.

David D. O'Toole Insider Trading History at Opiant Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2023	Sell	541	$20.26	$10,960.66	34,248
1/9/2023	Sell	415	$20.20	$8,383.00	34,789
1/5/2023	Sell	1,600	$20.20	$32,320.00	35,204
7/14/2022	Sell	779	$11.10	$8,646.90	36,804
1/10/2022	Sell	432	$30.60	$13,219.20
9/14/2021	Buy	200	$19.12	$3,824.00
8/16/2021	Buy	600	$15.38	$9,228.00	23,815
6/11/2020	Buy	1,000	$8.64	$8,640.00
5/26/2020	Buy	1,000	$10.90	$10,900.00
11/15/2019	Buy	1,100	$14.10	$15,510.00
8/15/2019	Buy	1,000	$15.20	$15,200.00
8/13/2019	Buy	1,000	$15.46	$15,460.00
8/14/2018	Buy	1,015	$15.40	$15,631.00
5/16/2018	Buy	2,000	$16.95	$33,900.00
5/11/2018	Buy	3,000	$18.85	$56,550.00

David D. O'Toole Buying and Selling Activity at Opiant Pharmaceuticals

Opiant Pharmaceuticals Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Today's Range

Now: N/A

50 Day Range

MA: $20.58

$20.03

$21.10

2 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.